MétaCan
Menu
Back to cohort
Record W4206407332 · doi:10.1002/alz.051113

Generation of the AD Informer Set: Chemical tools to facilitate Alzheimer’s disease drug discovery

2021· article· en· W4206407332 on OpenAlexaff
Frances Potjewyd, Joel K. Annor‐Gyamfi, Shiva Krishna Reddy Guduru, Felix Nwogbo, David A. Rogers, Meghan D. Hopkins, Ivie L. Conlon, Carrow I. Wells, Michael A. Stashko, Brian Hardy, Xiaodong Wang, Kevin J. Frankowski, Dmitri Kireev, Kenneth H. Pearce, Timothy M. Willson, Jeff Aubé, Stephen V. Frye, Timothy I. Richardson, Jessica E. Young, Alison D. Axtman

Bibliographic record

VenueAlzheimer s & Dementia · 2021
Typearticle
Languageen
FieldMedicine
TopicCholinesterase and Neurodegenerative Diseases
Canadian institutionsStructural Genomics Consortium
Fundersnot available
KeywordsDiseaseDrug discoverySet (abstract data type)Computational biologyMedicineAlzheimer's diseaseClinical trialNeuroscienceBioinformaticsComputer scienceBiologyPathology

Abstract

fetched live from OpenAlex

Abstract Background Currently, treatments for Alzheimer’s disease (AD) predominantly include acetylcholinesterase inhibitors, which address the symptomatic effects of the disease. The discovery of disease modifying interventions in the development and progression of AD are critical as there are currently no drugs or biologics which can elicit disease modifying effects. Promisingly there is an increase in the number of novel therapeutic strategies targeting AD that have progressed to clinical trials, and interrogation of targets implicated in AD pathology remains an area of extensive research. Method To assist the discovery of novel strategies that slow or halt AD pathology we have generated the AD Informer Set, the first iteration of which contains more than 150 chemical tools. We will make solutions of the physical set as well as all associated data available to the scientific community in 2021. Further data is being collected on compound kinetic solubility, pharmacokinetic properties, potential off‐target liabilities, and AD‐specific readouts, including mitochondrial metabolism, oxidative stress and glycolysis, and effects on p‐Tau and Aβ expression levels. Result The AD Informer Set includes compounds for targets that have AD implicated biology, either well validated or recently suggested, and contains relevant information about the gene, compound structure and activity, and associated AD phenotypes. 1, 2 Conclusion The AD Informer Set will be shared with the scientific community at large to qualify assays, interrogate target validity in AD models, and to provide positive controls to aid in the discovery of new chemical entities. References: (1) Hodes RJ, Buckholtz N. Accelerating Medicines Partnership: Alzheimer's Disease (AMP‐AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data Sharing. Expert Opin Ther Targets. 2016, 20, 389‐91. PMID: 26853544. (2) Mullard A. NIH launches open science Alzheimer initiative. Nat Rev Drug Discov. 2019, 18, 895. PMID: 31780852.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.021
Threshold uncertainty score0.071

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.010
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0050.002
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.003
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0210.008

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.128
GPT teacher head0.315
Teacher spread0.187 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicCholinesterase and Neurodegenerative DiseasesFrench-language works237,207